



Announcement Summary

Entity name
PHARMAXIS LTD

Date of this announcement
Friday December 02, 2022

The +securities the subject of this notification are:
☒ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	NED Options	9,000,000	02/12/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PHARMAXIS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

75082811630

1.3 ASX issuer code

PXS

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

2/12/2022



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☒ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☒ does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code

New class - code to be confirmed

+Security description

NED Options

+Security type

Options

ISIN code**Date the +securities the subject of this notification were issued**

2/12/2022

Will all the +securities issued in this class rank equally in all respects from their issue date?☒ Yes**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**☒ Yes**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Malcolm McComas	Bunyula Super Fund Pty Ltd (Bunyula Super Fund a/c)	3,000,000
Neil Graham	Biopharma Medicines Pharma LLC	3,000,000
Kathleen Metters	same	3,000,000

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?☒ No**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**<https://www.pharmaxis.com.au/assets/Documents/pdf/02022/ASX/2022-10-28-PXS-Notice-of-AGM-2022.pdf>

Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.11000000	1/12/2027

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other



Description

Pharmaxis Ordinary Shares

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://www.pharmaxis.com.au/assets/Documents/pdf/02022/ASX/2022-10-28-PXS-Notice-of-AGM-2022.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue details

Number of +securities

9,000,000

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
PXS : ORDINARY FULLY PAID	634,602,030

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
PXSAAP : OPTION EXPIRING 06-JUN-2023 EX NIL PRICE	66,500
PXSAAS : PERFORMANCE RIGHTS	29,872,075
New class - code to be confirmed : NED Options	9,000,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☒ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

29/11/2022